OneMain Financial (OMF) Prices 8M Share Secondary Offering at $53.50/Sh
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/12/2026
- S&P 500 ends higher as CoreWeave results fuel AI optimism
- Oil prices edge up as investors weigh US-Iran talks deadlock against lower demand
- CoreWeave soars after fifth straight quarter of record revenue, raised guide
- Four key things investors will watch in Nvidia's earnings next week
- Silver could surge to $90 as investment demand takes over, Citi says
- Lumentum Holdings (LITE) Tops Q4 EPS by 28c, Beats on Revenue; Offers Q1 Guidance
- Crude Inventory Rose 17.2 Million Barrels Last Week - EIA
- Aurora Cannabis rejects Curaleaf's unsolicited $4-per-share takeover bid
- AbCellera Biologics (ABCL) PT Raised to $30 at Truist on 'best-in-class potential'
- Comscore plans restructuring with $20M-$25M in cost cuts
- After-Hours Movers: CSCO, COHR, HLIT, CBRS, STUB, ENS
- After-Hours Movers: CRWV, NBIS, SMCI, LITE, CAVA, HRB
- After-Hours Movers: P, RIOT, BW, RKLB, HIMS, UPWK
- After-Hours Movers: TEAM, NET, TWLO, DOCS, FROG, DV, TTD, ABNB, DKNG, SG, RKT
- After-Hours Stock Movers: WDC, SNDK, FIG, APP, HUBS, SOUN, DASH, XYZ, Z, FLNC
Pre-Open Stock Movers 04/29: (VER) (OSTK) (FB) Higher; (ADVM) (CTXS) (EBAY) Lower (more...)
April 29, 2021 9:20 AM EDTToday's Pre-Open Stock Movers:
Adverum Biotechnologies, Inc. (Nasdaq: ADVM) 54% LOWER; announced a Suspected Unexpected Serious Adverse Reaction (SUSAR) of hypotony (clinically-relevant decrease in ocular pressure) in its INFINITY clinical trial evaluating ADVM-022 gene therapy for the treatment of diabetic macular edema (DME). This event occurred 30 weeks after randomization in one patient treated with a single intravitreal injection of the high dose (6 x 10^11 vg/eye) of ADVM-022 who has developed hypotony, with panuveitis and loss of vision in the treated eye.
Galera Therapeutics, Inc. (Nasdaq:... More
After-Hours Stock Movers 04/28: (GRTX) (AZPN) (CAKE) Higher; (ADVM) (CMCO) (HOLX) Lower (more...)
April 28, 2021 5:45 PM EDTToday's After-Hours Movers:
Adverum Biotechnologies, Inc. (Nasdaq: ADVM) 54% LOWER; announced a Suspected Unexpected Serious Adverse Reaction (SUSAR) of hypotony (clinically-relevant decrease in ocular pressure) in its INFINITY clinical trial evaluating ADVM-022 gene therapy for the treatment of diabetic macular edema (DME). This event occurred 30 weeks after randomization in one patient treated with a single intravitreal injection of the high dose (6 x 10^11 vg/eye) of ADVM-022 who has developed hypotony, with panuveitis and loss of vision in the treated eye.
Galera Therapeutics, Inc. (Nasdaq:... More
OneMain Financial (OMF) Announces Proposed 8M Share Secondary Offering of Common Stock
April 28, 2021 5:13 PM EDTOneMain Holdings, Inc. (NYSE: OMF) (the Company) announced today the commencement of a proposed secondary public offering of 8,000,000 shares of the Companys common stock by certain entities managed by affiliates of Apollo Global Management, Inc. and Värde Partners, Inc. (together, the selling stockholders). The 8,000,000 shares of... More
OneMain (OMF) PT Raised to $72 at Credit Suisse
April 28, 2021 6:05 AM EDTCredit Suisse analyst Moshe Orenbuch raised the price target on OneMain (NYSE: OMF) to $72.00 (from $69.00) while maintaining a Outperform rating.... More
OneMain (OMF) PT Raised to $72 at Barclays
April 28, 2021 5:38 AM EDTBarclays analyst Mark DeVries raised the price target on OneMain (NYSE: OMF) to $72.00 (from $69.00) while maintaining a Overweight rating.... More
